“…TMPO-AS1 was reported to be significantly upregulated in various cancers, such as lung cancer (Yu et al, 2020), breast cancer (Mitobe et al, 2020), colorectal cancer (CRC) (Mohammadrezakhani et al, 2020), hepatocellular carcinoma (HCC) (Liu and Shen, 2020;Wang et al, 2020), gastric cancer (GC) (Sun and Han, 2020), bladder cancer (He et al, 2020b), laryngeal squamous cell carcinoma (LSCC) (Zhang et al, 2020b), ovarian cancer (Li et al, 2020a;Zhao et al, 2020), thyroid cancer (Li et al, 2020b), esophageal cancer (Gao et al, 2020), Wilms tumor (Zhang et al, 2020a), cervical cancer (Gang et al, 2020), retinoblastoma (Peng et al, 2020), osteosarcoma (Cui and Zhao, 2020), or prostate cancer (Huang et al, 2018), and functions as an oncogene in carcinogenesis and tumor progression. To further investigate the aberrant expression of TMPO-AS1 in various cancers and their associated prognosis, this study applied the Gene Expression Profiling Interactive Analysis (GEPIA) online data analysis tool (Tang et al, 2017).…”